Hitachi Announces Pharmacotherapy Outcome Prediction Technology for Drug Selection Support in Type-2 Diabetes Mellitus
2017年11月7日 - 10:53AM
JCN Newswire (英)
Hitachi, Ltd. (TSE:6501) today announced the development of a
machine learning-based outcome prediction and comparison technology
that predicts with high accuracy the success and failure of various
medication options for patients with type-2 diabetes mellitus
(T2DM), in collaboration with University of Utah Health (U of U
Healt). The technology analyzes electronic medical records and
creates a prediction model which calculates the probability of
different medications attaining a target value for hemoglobin A1c
(HbA1c)(1) after 90 days of commencing treatment, thus potentially
helping medical practitioners choose the most effective medication
option. The high accuracy(2) of the technology in predicting the
effectiveness of various medications was confirmed using simulation
on past records of patients with diabetes.
Currently, the importance of value-based healthcare, which aims to
realize both better outcomes while reducing healthcare costs, is
receiving attention worldwide. In the United States, the number of
patients with diabetes has risen to about 23 million, and one in
four people over the age of 65 is diagnosed with T2DM(3). Treatment
of T2DM spans from several months to several years or more, during
which time the drug(s) selected and the dosage(s) need to be
adjusted based on the patient's condition. This significant
variability in pharmacotherapy regimens often leads to a
trial-and-error approach in drug selection.
Hitachi has been working on developing various measures to address
diabetes using IT, such as life-style modification support and
diabetes prevention services(4). In this research collaboration,
the knowledge and experience of Hitachi, and doctors, pharmacists
and biomedical informaticists at the U of U Health, were used to
develop technology to predict the probability of achieving a
treatment target with each medication. In developing the
technology, data from approximately 6,800 patients were analyzed
chronologically from various aspects such as drug category, dosage,
treatment period, weight, trend in test results, etc. Machine
learning techniques were then applied to the resulting information
to build a prediction model for HbA1c, generating patient-specific
predictions of the effectiveness of alternate treatment options.
Using the resulting model, it is possible to predict and compare
the effectiveness of treatment at 90-days, a common period in the
United States between clinic visits for patients whose diabetes
therapy is being adjusted. As a result, the technology has the
potential to support the selection of the most effective medication
depending on the patient's background and condition. The technology
was verified using data from another 2,200 patient files by
simulation, and the highly accurate nature of the predictions was
confirmed.
Hitachi will continue this collaborative research with U of U
Health to realize the practical application of this technology and
its development of healthcare informatics technologies that support
medical practitioners and patients with improved healthcare
outcomes(5). Additionally, part of these results will be presented
at the IEEE-NIH Special Topic Conference on Healthcare Innovation
and Point-of-Care Technologies to be held from 6th to 8th November
2017, in Bethesda, Maryland, U.S.A.
(1) HbA1c:Laboratory test value which reflects average blood sugar
level for the past two to three months.
(2) AUC (Area Under the Curve) of 0.85. The area under the Receiver
Operator Curve (ROC) represents prediction model performance with a
value range from 0.5 to1 (ideal).
(3) Centers for Disease Control and Prevention. National Diabetes
Statistics Report, 2017. Atlanta, GA: Centers for Disease Control
and Prevention, U.S. Dept of Health and Human Services; 2017
(4) For more information on Hitachi's services, please reference:
Proof of Concept Project for a Diabetes Prevention Service in
Greater Manchester, United Kingdom. A Hitachi Review, 64 (No.
1):
(5) Implementation of this technology will require due diligence to
ensure sufficient protection of personal information and
privacy.
About University of Utah Health
University of Utah Health is the state's only academic health care
system, providing leading-edge and compassionate medicine for a
referral area that encompasses 10% of the U.S. A hub for health
sciences research and education in the region, U of U Health has a
$291 million research enterprise and trains the majority of Utah's
health care professionals at its Schools of Medicine and Dentistry
and Colleges of Nursing, Pharmacy and Health. Staffed by more than
20,000 employees, the system includes 12 community clinics and four
hospitals. For eight straight years, U of U Health has ranked among
the top 10 U.S. academic medical centers in the Vizient Quality and
Accountability Study, including reaching No. 1 in 2010 and
2016.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE:6501), headquartered in Tokyo, Japan, delivers
innovations that answer society's challenges with our talented team
and proven experience in global markets. The company's consolidated
revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761
billion yen ($81.3 billion). Hitachi is focusing more than ever on
the Social Innovation Business, which includes power &
infrastructure systems, information & telecommunication
systems, construction machinery, high functional materials &
components, automotive systems, healthcare and others. For more
information on Hitachi, please visit the company's website at
www.hitachi.com.
Source: Hitachi, Ltd.
Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111
Copyright 2017 JCN Newswire . All rights reserved.